Clinical Trial Update: Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing letermovir to valganciclovir for prevention of CMV disease in kidney transplant recipients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cmv Disease
• Cytomegalovirus Infection
• Kidney Transplant Recipients

Drugs mentioned

• Letermovir (letermovir)
• Valganciclovir (Valganciclovir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: CMV Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-04-14